NCT03594435View on ClinicalTrials.gov

Ibudilast for the Treatment of Alcohol Use Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

April 19, 2023

Study Completion Date

April 19, 2023

Conditions
Alcohol Use Disorder
Interventions
DRUG

Ibudilast

targets neurotrophin signaling and neuroimmune function

DRUG

Placebo oral capsule

matched to active drug, ibudilast

Trial Locations (1)

90095

UCLA Addictions Laboratory, Los Angeles

Sponsors

Collaborators (1)

MediciNova
All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

collaborator

MediciNova

INDUSTRY

lead

University of California, Los Angeles

OTHER

NCT03594435 - Ibudilast for the Treatment of Alcohol Use Disorder | Biotech Hunter | Biotech Hunter